[Hormonal contraception has no effect on the atherogenicity of blood lipids: results of a prospective open-label multicenter study in 1321 patients].
In a prospective open-label multicenter trial, safety, tolerance, cycle control and changes in lipid metabolism before and during intake of a low-dose hormonal contraceptive (gestodene 75 mcg + ethinylestradiol 30 mcg) have been investigated under normal conditions of a general or gynecology practice (232 testing physicians, 1321 women). The atherogenic index remained almost unchanged over six cycles observed (3.3 before drug intake vs. 3.28 after drug intake, cycle 6). HDL cholesterol levels increased significantly in the period between prestudy and cycle 6 (+4.4%, p < 0.0001). A very good cycle control was demonstrated, and reliable contraception was achieved, combined with excellent general tolerance. The preparation conclusively suits very well for oral hormonal contraception.
Kunz
J
J
Schweizerische Pflegerinnenschule, Gynäkologisch-Geburtshilfliche Abteilung, Zürich.
Jaeger
A
A
D000328:Adult; D001161:Arteriosclerosis / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D009652:Norpregnenes / Q000009:adverse effects / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000494:pharmacology; D011446:Prospective Studies
D003277:Contraceptives, Oral, Combined; D008055:Lipids; D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D004997:Ethinyl Estradiol
Hormonale Kontrazeption hat keinen Einfluss auf die Atherogenität der Serumlipide: Resultate einer prospektiven Open-label-Multizenterstudie an 1321 Probandinnen.